Welcome to DukeHealth.org.
Skip over navigation
Skip over navigation
- Home
- Patient and Visitor Info
- Physicians
- Services
- Clinical Trials
- Event Calendar
- Locations
- Health Library
- About Duke Medicine
Quick Links
Home
>
Clinical Trials
>
Phase 3 study to evaluate the efficacy and safety of Brodalumab compared with placebo and ustekinumab in subjects with moderate to severe plaque psoriasis
Phase 3 study to evaluate the efficacy and safety of Brodalumab compared with placebo and ustekinumab in subjects with moderate to severe plaque psoriasis
Share
Adults 18-75 with moderate to severe plaque psoriasis. Injectable medications being compared (Stelara versus Ustekinumab). 1/6 chance of Placebo. ALL subjects treated with active study drug by week 12. Compensation for time and travel.
(REF# 00038071)
For more information, contact Kim Scoggins at (919)684-1830.
(REF# 00038071)
